The bill establishes a federal private cause of action for people who received gender-related medical treatment while under 18, permitting suits against each person who performed that care and allowing guardians or estate representatives to bring claims for others. It pairs that remedy with a statutory damages option, fee-shifting, and a set of jurisdictional triggers tied largely to interstate commerce.
The statute defines ‘‘gender-related medical treatment’’ by listing surgical procedures, hormones, and puberty blockers for both sexes and gives the Secretary of Health and Human Services authority to identify additional covered treatments; it also carves out treatments for diagnosed disorders of sex development. The definitions of ‘‘sex,’’ ‘‘gender,’’ ‘‘female,’’ and ‘‘male’’ are expressed in biological, reproductive terms that depart from contemporary clinical usage—an important detail for providers, payers, and compliance teams evaluating exposure and credentialing risks.
At a Glance
What It Does
Creates a federal civil right of action allowing an individual who received gender-related medical treatment as a minor to sue each person who performed the treatment in federal court, and permits recovery of actual damages or a statutory award plus attorney’s fees. The bill sets multiple jurisdictional hooks tied to interstate commerce activity to establish federal jurisdiction.
Who It Affects
Medical practitioners, surgeons, clinics, telemedicine prescribers, and any entity or person who performed gender-related treatments on minors; parents and guardians who consented to care; and payers and hospitals that facilitated or financed such care. HHS gains an administrative role to designate additional covered treatments.
Why It Matters
This is a federal private enforcement vehicle tied to a detailed statutory definition of covered procedures and a biologically framed definition of sex and gender; it changes civil exposure for providers and could influence provider decisions, insurance coverage, and institutional credentialing even though it does not address criminal liability or licensing directly.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill gives people who were minors when they received gender-related medical treatment a new federal civil claim against the person or persons who performed that treatment. A claimant can sue in federal district court if one of a list of interstate-commerce-related predicates is met (for example, use of mail, wire or other channels across state lines, payments that traverse interstate commerce, or use of items that traveled in interstate commerce).
If the claimant is under 18, incapacitated, deceased, or otherwise unable to sue, a guardian, estate representative, family member, or court-appointed person can bring the claim on their behalf.
Remedies under the bill include recovery of actual damages or an express statutory alternative: a liquidated amount per instance of treatment plus costs and reasonable attorney’s fees. The statute ties recovery to ‘‘instances’’ of gender-related care but does not define ‘‘instance’’ or set a statute of limitations, leaving the timing and aggregation of claims to later litigation.
The bill also specifies that suits may proceed against ‘‘each person who performed the gender-affirming care,’’ making individual clinicians and procedural operators direct targets of liability.The heart of the bill is its definition section. ‘‘Gender-related medical treatment’’ is enumerated extensively for both female-presenting and male-presenting individuals, naming multiple surgical procedures (for example, mastectomy, vaginoplasty, phalloplasty, orchiectomy, facial feminization), exogenous hormone therapies, and puberty blockers (including GnRH agonists). The Secretary of Health and Human Services is empowered to add other treatments to the statutory list.
The statute separately excludes care provided to treat diagnosed disorders of sex development (DSD) and care for ambiguous biological sex characteristics, plus treatment of an infection or adverse condition caused by prior gender-related treatment.Finally, the bill contains detailed provisions redefining key terms: it treats ‘‘sex’’ and ‘‘gender’’ as biological and largely synonymous for statutory purposes and supplies reproductive-based definitions of ‘‘male’’ and ‘‘female.’’ Those definitional choices will matter in litigation over coverage and scope because they depart from clinical and administrative understandings of gender identity, and the bill includes a drafting anomaly — an internal cross-reference that appears to point to a non‑existent paragraph — that creates an immediate drafting and interpretive question for courts and litigants.
The Five Things You Need to Know
The bill permits plaintiffs to recover either actual damages or a liquidated damages award of $250,000 for each instance of gender-related treatment performed while the plaintiff was a minor, plus costs and reasonable attorney’s fees.
Federal jurisdiction requires a commerce-connected predicate such as interstate travel by the defendant or victim, use of interstate communication channels, payments crossing state lines, use of items that traveled in interstate commerce, or conduct affecting U.S. territories or other interstate commerce.
‘‘Gender-related medical treatment’’ is explicitly defined to include listed surgeries (e.g.
mastectomy, vaginoplasty, phalloplasty), exogenous sex hormones (estrogen, testosterone), and puberty blockers (including GnRH agonists); the Secretary of HHS may add other treatments to this list.
The statute excludes medical treatment provided to diagnose or treat disorders of sex development (DSD) and care for irresolvably ambiguous biological sex characteristics, and it excludes treatment for infections or conditions caused or worsened by prior gender-related treatment.
The bill defines ‘‘gender’’ and ‘‘sex’’ as biological, reproductive categories and provides reproductive-based definitions of ‘‘male’’ and ‘‘female,’’ rather than using language about gender identity or expression.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the legislation as the ‘‘Gender-Affirming Child Abuse Prevention Act.’
Private right of action and representation
Creates the core cause of action: an individual who received gender-related medical treatment while a minor may sue each person who performed that care in federal court, subject to commerce-related jurisdictional predicates. If the injured person is under 18, incompetent, incapacitated, or deceased, the statute expressly permits guardians, estate representatives, family members, or a court-appointed suitable person to bring the claim on the individual’s behalf, broadening who can assert the claim and potentially lengthening the period during which claims can be filed via estate actions.
Remedies and federal jurisdiction triggers
Sets recovery options as actual damages or a statutory liquidated amount per ‘instance’ of treatment and mandates payment of litigation costs and reasonable attorney’s fees. Federal jurisdiction is anchored to a non-exhaustive list of interstate-commerce-oriented predicates—travel in interstate commerce, use of communications or payment channels, use of items that traveled in interstate commerce, actions within U.S. territorial jurisdiction, or conduct otherwise affecting interstate commerce—so claimants must show one of these links to secure a federal forum.
Definition: gender-related medical treatment (enumeration and HHS role)
Provides an extensive, itemized list of treatments covered for both sexes: named surgical procedures, implantable prostheses, exogenous hormones, and puberty blockers. The Secretary of Health and Human Services may identify additional treatments that fall under the definition, giving the executive branch a role in expanding (or clarifying) the scope beyond the statutorily listed items; that delegation will shape future coverage and litigation if HHS acts.
Key statutory exclusions
Carves out care provided for diagnosed disorders of sex development (DSD) as established by genetic or biochemical testing, care for irresolvably ambiguous biological sex characteristics, and treatment of infections, injuries, diseases, or disorders caused or exacerbated by prior gender-related medical treatment. Those exclusions narrow the universe of actionable claims but will require factual and medical adjudication about diagnoses and causation.
Definitions of sex, gender, male, female, and minor
Defines ‘‘sex’’ and ‘‘gender’’ as biological categories and supplies reproductive-system-based definitions of ‘‘male’’ and ‘‘female,’’ and sets ‘‘minor’’ at under 18. The statutory choice to equate gender with biological sex and to use reproductive criteria departs from many clinical and administrative definitions, which may affect how courts interpret eligibility for claims and how medical records or expert testimony are used to establish whether a listed treatment was performed for a covered purpose.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals who received gender-related treatment as minors: the bill gives them a federal private cause of action and a capped statutory damages alternative, enabling monetary recovery and fee-shifting to pursue claims.
- Guardians, estate representatives, and family members: authorized to bring claims on behalf of minors, incapacitated persons, or decedents, which extends access to remedies where the injured person cannot litigate personally.
- Litigation counsel and plaintiff-side advocates: the statutory damages option and fee-shifting make contingency litigation more commercially viable and create a new practice area focused on historical care.
Who Bears the Cost
- Clinicians and surgical teams who provided gender-related treatments to minors: named as direct defendants to whom liability may attach for each instance of care, increasing malpractice and direct liability exposure.
- Clinics, hospitals, and telemedicine providers: institutions that facilitated or hosted procedures or prescribing may face suits and increased insurance or risk-management costs; coordination across state lines raises compliance burdens.
- Insurers and payers: increased claim exposure and litigation risk can raise premiums, prompt coverage disputes, and pressure payers to alter prior-authorization rules or carve out certain services for minors.
- Federal agencies and courts: HHS has a delegated role to identify additional covered treatments, creating administrative workload, and federal courts will see new civil litigation tied to medical evidence and interstate-jurisdiction fact-finding.
Key Issues
The Core Tension
The central dilemma is this: the bill seeks to create a federal remedy to hold providers accountable for gender-related medical treatments performed on minors, but in doing so it substitutes a statutory, reproductive-focused framework for clinical definitions and grants sweeping liability exposure that could chill medical practice and parental decision-making; resolving whether protecting minors from allegedly harmful interventions justifies imposing broad private liability on clinicians and institutions is a trade-off with no simple legal or policy answer.
The bill packs consequential choices into a short statutory framework and leaves several operational and legal questions unresolved. First, the definitional approach—the bill’s equation of gender with biological sex and reproductive-based definitions of ‘male’ and ‘female’—is narrower than clinical definitions used in medical practice and by many health systems; that mismatch will create disputes over whether a treatment fell within the statute’s text or was provided for a non-covered purpose.
Second, the federal jurisdictional mechanism depends on broadly phrased interstate-commerce predicates; while those hooks are expansive, plaintiffs will still need to trace particular interstate activities (payments, communications, travel, or items) to secure a federal forum, creating case-by-case litigation on venue and jurisdiction.
Third, the statute offers a per-instance liquidated damages amount and fee-shifting but omits key procedural rules: it does not define ‘‘instance,’’ specify a statute of limitations, address retroactivity, or state whether parental consent, contemporaneous medical necessity determinations, or adherence to accepted standards of care are defenses. Those gaps invite litigation over aggregation of claims, timing, and proof standards and may produce uneven outcomes across districts.
Finally, the bill delegates to HHS the authority to add other treatments to the covered list without specifying criteria or a process for addition, creating administrative discretion that will be politically and legally significant and that may itself become the focus of litigation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.